Dr. Navar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-633-5555Fax+1 214-645-6757
Education & Training
- Duke University HospitalFellowship, Cardiovascular Disease, 2013 - 2016
- Duke University HospitalResidency, Internal Medicine/Pediatrics, 2009 - 2013
- Duke University School of MedicineClass of 2009
Certifications & Licensure
- TX State Medical License 2020 - 2026
- NC State Medical License 2009 - 2021
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Publications & Presentations
PubMed
- Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial.Stephen J Nicholls, Wei Ni, Grace M Rhodes, Steven E Nissen, Ann Marie Navar
JAMA. 2025-01-21 - Lipid Management in US Commercial and Medicare Enrollees with Atherosclerotic Cardiovascular Disease: Treatment Patterns and Low-Density Lipoprotein Cholesterol Control.Ann Marie Navar, Batul Electricwala, Jasjit K Multani, Zifan Zhou, Chi-Chang Chen
The American Journal of Cardiology. 2025-01-16 - 1 citationsAchievement of LDL-C <55 mg/dL among US adults: Findings from the cvMOBIUS2 registry.Ann Marie Navar, Nishant P Shah, Peter Shrader, Laine E Thomas, Zahid Ahmad
American Heart Journal. 2025-01-01
Journal Articles
- Choosing an Initial Therapeutic Approach for Hypertension—Time for a Fixed-Dose Combination First?Ann Marie Navar, Thomas J Wang, JAMA Cardiology
- Heroism in the Face of the COVID-19 PandemicAjay J Kirtane, Ann Marie Navar, JAMA Cardiology
- Moving Beyond Regression Techniques in Cardiovascular Risk Prediction: Applying Machine Learning to Address Analytic ChallengesAnn Navar, MD, European Heart Journal
Authored Content
- How Real-World Data Augments What We Know About SGLT-2 Inhibitors for Cardiovascular Risk ReductionSeptember 2020
- Choosing an Initial Therapeutic Approach for Hypertension—Time for a Fixed-Dose Combination First?July 2020
- Heroism in the Face of the COVID-19 PandemicJune 2020
Press Mentions
- Apolipoprotein B Test May Be More Accurate Measure of Heart Disease RiskAugust 14th, 2024
- Pregnant Cardiology Trainees Report High Complication Rates, Lack of Radiation SafetyAugust 9th, 2024
- Fish Oil Labels Make Health Claims, Despite Lack of DataSeptember 18th, 2023
- Join now to see all
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: